Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Templated Insertion Mediates Generation of p190 BCR/ABL Facilitating CML Heterogeneity Uniquely Detected By Optical Genome Mapping

Chezi Ganzel, Yishai Ofran, Bayan Alyan, Elina D Shnayder, Shira Vanunu, Zakaria M Sous, Victoria Vinokurov, Veronika Butin Israeli

Blood (2024) 144 (Supplement 1): 6577.

https://doi.org/10.1182/blood-2024-209728

Published: 2024

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Ellen Broide, Emmanuel Benayoun, Jacob M. Rowe, Yishai Ofran

Blood (2023) 142 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2023-185052

Published: 2023

Journal Articles

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Vladimir Vainstein, Arnon Haran, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2023-179194

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

NT-Probnp and High-Sensitivity Troponin T Fail to Detect Cardiac Involvement in Erdheim-Chester Disease

Levi-Dan Azoulay, Chezi Ganzel, Marine Bravetti, Zahir Amoura, Jean Donadieu, Philippe Cluzel, Fleur Cohen-Aubart, Julien Haroche

Blood (2022) 140 (Supplement 1): 3997–3998.

https://doi.org/10.1182/blood-2022-157532

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Erythrophagocytosis in a young adult with mycoplasma pneumonia–induced paroxysmal cold hemoglobinuria

Dor Eldar, Chezi Ganzel

Blood (2021) 137 (10): 1432.

https://doi.org/10.1182/blood.2020009745

Published: 2021

Journal Articles

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139670

Published: 2020

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Boaz Nachmias, MD PhD, Geremy Godefroy, MD, Chezi Ganzel, MD, Neta Goldschmidt, MD, Eyal Rozenbach, MD, Rachel Bar-Shalom, MD, Diana Libster, MD, Vladimir Vainstein, MD

Blood (2019) 134 (Supplement_1): 5358.

https://doi.org/10.1182/blood-2019-121473

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

NARROW

Templated Insertion Mediates Generation of p190 BCR/ABL Facilitating CML Heterogeneity Uniquely Detected By Optical Genome Mapping

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

NT-Probnp and High-Sensitivity Troponin T Fail to Detect Cardiac Involvement in Erdheim-Chester Disease

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Erythrophagocytosis in a young adult with mycoplasma pneumonia–induced paroxysmal cold hemoglobinuria

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only